Table 1.
Baseline characteristics of study participants (n=368 097)
| Tested for LTBI (n=37 268) | Not tested for LTBI (n=330 829) | |
|---|---|---|
| Age, years | ||
| 16–25 | 16 396/37 051 (44·0%) | 180 334 (54·5%) |
| 26–35 | 20 655/37 051 (55·4%) | 150 495 (45·5%) |
| Sex | ||
| Female | 16 518/36 579 (45·2%) | 162 190/330 823 (49·0%) |
| Male | 20 061/36 579 (54·8%) | 168 633/330 823 (51·0%) |
| ETS region of origin | ||
| Africa | 4297/22 546 (19·1%) | 90 668 (27·4%) |
| The Americas or Europe | 306/22 546 (0·8%) | 10 153 (3·1%) |
| East and southeast Asia | 606/22 546 (2·7%) | 25 787 (7·8%) |
| South Asia | 17 337/22 546 (76·9%) | 204 221 (61·7%) |
| Tuberculosis incidence in country of origin (cases per 100 000)* | ||
| 40–149 | 2138/22 546 (9·5%) | 46 456 (14·0%) |
| 150–349 | 19 757/22 546 (87·6%) | 258 595 (78·2%) |
| >350 | 651/22 546 (2·9%) | 25 778 (7·8%) |
| Tuberculosis incidence in area of residence (cases per 100 000)† | ||
| ≤9·2 | 3132/33 789 (9·3%) | 35 936/319 090 (11·3%) |
| 9·3–31·6 | 14 016/33 789 (41·5%) | 203 003/319 090 (63·6%) |
| >31·6 | 16 641/33 789 (49·2%) | 80 151/319 090 (25·1%) |
| Deprivation index | ||
| 1–3 deciles (most deprived) | 21 579/35 948 (60·0%) | 161 651/323 764 (49·9%) |
| 4–6 deciles | 11 791/35 948 (32·8%) | 120 217/323 764 (37·1%) |
| 7–10 deciles (least deprived) | 2578/35 948 (7·2%) | 41896/323 764 (12·9%) |
| Year of arrival in England or primary care registration | ||
| 2011–12 | 1882/22 546 (8·3%) | 76 342 (23·1%) |
| 2013–14 | 2610/22 546 (11·6%) | 58 853 (17·8%) |
| 2015–16 | 6910/22 546 (30·1%) | 84 178 (25·4%) |
| 2017–18 | 11 144/22 546 (49·4%) | 111 456 (33·7%) |
| Pre-entry screening for active tuberculosis | ||
| Yes | 7704 (20·7%) | 80 641 (24·4%) |
| No | 29 564 (20·7%) | 250 188 (75·6%) |
| IGRA for latent tuberculosis | ||
| Positive | 6640 (17·8%) | NA |
| Negative | 29 892 (80·2%) | NA |
| Indeterminate | 353 (0·9%) | NA |
| No result available | 383 (1·0%) | NA |
| LTBI treatment | ||
| Yes | 1740 (26·2%) | NA |
| No | 4900 (73·8%) | NA |
Data are n (%) or n/N (%). ETS=enhanced tuberculosis surveillance system. IGRA= interferon-γ release assay. LTBI=latent tuberculosis infection. NA=not applicable.
*
WHO estimated tuberculosis incidence.13
†
The UK Health Security Agency estimated tuberculosis incidence in Clinical Commissioning Group area of residence.